Detection of Azole Resistance Inducing Mutations on DNA Extracted Directly From Serum or Plasma of Immunocompromised Patients With an Invasive Aspergillus Infection Azole Resistance PCR Optimalization-study

Status: Recruiting
Location: See location...
Intervention Type: Diagnostic test
Study Type: Observational
SUMMARY

Invasive aspergillosis (IA) is the most common mould infection in immunocompromised patients with haematological disease. Voriconazole, a triazole, improves overall survival of patients with an IA and is the mainstay of therapy. Resistance of A. Fumigatus emerged as an important clinical problem and infections with azole resistant Aspergillus have a high mortality. Nowhere in the world, azole resistance is more prevalent than in the Netherlands. Rapid detection of resistance is key to improve the patient's outcome but fungal cultures take time and are often negative. The investigators aim to detect azole resistance associated mutations in fungal DNA extracted directly from serum or plasma to accelerate diagnosis and improve outcome of patients infected with azole resistant A. fumigatus.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
View:

• 18 years or older.

• Lung CT shows lesions that fulfil the EORTC/MSG radiological criteria of possible invasive fungal infection.

• A bronchoalveolar lavage is planned or has been performed \<48hrs earlier

Locations
Other Locations
Netherlands
Erasmus Medical Center (EMC)
RECRUITING
Rotterdam
Contact Information
Primary
Bart Rijnders, MD, PhD
b.rijnders@erasmusmc.nl
+31107033510
Backup
Hanne Lamberink, MD
h.lamberink@erasmusmc.nl
Time Frame
Start Date: 2017-07-01
Estimated Completion Date: 2030-12-31
Participants
Target number of participants: 300
Related Therapeutic Areas
Sponsors
Leads: Bart Rijnders

This content was sourced from clinicaltrials.gov

Similar Clinical Trials